HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America

Journal of Cardiac Failure, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

---

Contemporary pharmacological treatment and management of heart failure

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(8), P. 545 - 555

Published: March 26, 2024

Language: Английский

---

Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction

Circulation, Journal Year: 2024, Volume and Issue: 149(7), P. 510 - 520

Published: Jan. 23, 2024

Guideline-directed medical therapies (GDMTs) are the mainstay of treatment for heart failure with reduced ejection fraction (HFrEF), but they underused. Whether sex differences exist in initiation and intensification GDMT newly diagnosed HFrEF is not well established.

Language: Английский

---

Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure

JACC Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Suspected de novo heart failure in outpatient care: the REVOLUTION HF study

European Heart Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Ambulatory patients presenting with signs or symptoms of heart failure (HF) should undergo natriuretic peptide testing. Rates death, HF hospitalization, and healthcare costs were examined in thus identified suspected de novo HF. This population-based study (REVOLUTION HF) encompassing two large regions Sweden who presented to outpatient care for the first time between 1 January 2015 31 December 2020, had a recorded sign (peripheral oedema) symptom (dyspnoea) HF, whose N-terminal pro-B-type (NT-proBNP) measured >300 ng/L within ±30 days that symptom. Characteristics, outcomes, patterns, these followed year. Comparisons made matched controls without history its signs, symptoms, elevated NT-proBNP. Overall, 5942 (median age 78.7 years; 54% women) Within year, 29% received diagnosis. Patients higher rates all-cause death (11.7 vs. 6.5 events/100 person-years) hospitalizations (12.5 2.2 than (n = 2048), highest event weeks after presentation. NT-proBNP levels. Although some already used guideline-directed medical therapies other indications, initiation new medications was variable. Healthcare controls, driven mostly by chronic kidney disease. high mortality morbidity presentation, accrued substantial costs, highlighting an urgent need prompt identification, evaluation, treatment

Language: Английский

---

Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD)

Kidney360, Journal Year: 2024, Volume and Issue: 5(3), P. 352 - 362

Published: Feb. 1, 2024

Key Points Newly detected, moderately progressed CKD is associated with high clinical risks and health care costs. Most patients do not have diabetes are at the same risk as those diabetes. Substantial inertia kidney-protective treatment observed when detected. Background Kidney-protective treatments (renin–angiotensin system inhibitors sodium–glucose cotransporter-2 [SGLT-2is]) can delay progression, cardiovascular events, death. Methods This observational cohort study used electronic records claims data from Japan, Sweden, United States to assess 1-year mortality/hospitalization event rates per 100 patient-years (PYs), cumulative hospital costs patient, use before/after SGLT-2i (dapagliflozin) approval for (2021) stage 3–4 with/without type 2 (T2D). Results Among 449,232 (across-country median age range 74–81 years), 79% did T2D. Prevalence ranges atherosclerotic disease heart failure were 20%–36% 17%–31%, respectively. Baseline inhibitor and/or SGLT-2i) was limited, especially among without Event (11.4–44.4/100 PYs) (7.4–22.3/100 PYs). Up 14.6% of had died within 1 year. Hospital higher than disease. After incident CKD, initiation low (8%–20%) discontinuation (16%–27%), Conclusions Incident substantial morbidity, mortality, costs, undertreatment, in T2D, who represented majority patients. highlights an urgent need early detection better moderate CKD.

Language: Английский

---

Implementation of guideline‐recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

European Journal of Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Abstract Aims Guidelines recommend immediate initiation of all four class I guideline‐directed medical therapies, renin–angiotensin system inhibitors (RASI) or angiotensin receptor–neprilysin (ARNI), beta‐blockers, mineralocorticoid receptor antagonists (MRA) and sodium–glucose cotransporter 2 (SGLT2i) following the diagnosis heart failure (HF) with reduced ejection fraction (HFrEF). The extent to which this occurs in new‐onset HFrEF is unclear. We assessed guideline‐recommended therapies during first year a diagnosis. Methods results Swedish HF Registry was linked additional national registries. In patients (ejection <40%), clinical characteristics treatment from when they were available recommended guidelines according time (<3, 3 <6, 6–12 >12 months). Of 55 581 enrolled between 2000 2021, 54%, 5.8%, 4.8% 36% had an duration <3, months, respectively. Patients shorter younger, lower New York Heart Association fewer cardiovascular comorbidities. Within <6 months diagnosis, 93%, 92%, 90% 89% on RASI ARNI, 9.8%, 17%, 19% 22% ARNI alone, 35%, 43%, 44% 46% MRA, 92% 91% 26%, 30%, 28% SGLT2i, Additionally, 18% received cardiac resynchronization therapy/implantable cardioverter‐defibrillator after Conclusions Most beta‐blockers Use MRA SGLT2i limited, both early later periods. Our findings suggest that strategies improve use remain urgently needed.

Language: Английский

---

Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart

BMJ Open, Journal Year: 2025, Volume and Issue: 15(2), P. e088998 - e088998

Published: Feb. 1, 2025

To evaluate the trend of prescription four foundational therapies, and their impact on 30-day urgent re-admissions all-cause death in patients with heart failure reduced ejection fraction (HFrEF) following an acute decompensation event. Retrospective. One tertiary referral centre. 999 consecutively admitted a primary diagnosis HFrEF between January 2020 June 2023 were identified through validated, high-performance technology infrastructure based artificial intelligence. The entire cohort was divided into three time periods two points: September 2021 (ie, release latest European guidelines) 2022 reimbursement for sodium-glucose cotransporter 2 (SGLT2) inhibitors). Trends predictors each therapies composite rehospitalisation causes at 30 days. Among included patients, β-blockers prescribed 93% ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin-neprilysin (ARNi) 73%, mineralocorticoid antagonist 30% SGLT2 inhibitors 18%. Over time, increase rate occurred only (3% vs 10% 32%, p<0.001), whereas days remained stable (9.9% 10.3% 8.4%; p=ns). In multivariate analysis, use ACEi/ARB/ARNi associated lower risk (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01). Conversely, furosemide discharge 2.25; 1.29 3.94; p<0.01) previous genitourinary infection 4.02; 1.67 9.68; higher rehospitalisation. our study, early adoption guideline-recommended medical therapy is still limited, significant rise SGLT2i prescriptions after readmissions restricted ACEi/ARB/ARNi.

Language: Английский

---

A Noninvasive System for Remote Monitoring of Left Ventricular Filling Pressures

JACC Basic to Translational Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Sex and clinical outcomes in new-onset heart failure

International Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 133092 - 133092

Published: March 1, 2025

Language: Английский

---